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Abstract. We investigate a scheme for noninvasive continuous monitoring of absolute cerebral blood flow
(CBF) in adult human patients based on a combination of time-resolved dynamic contrast-enhanced near-infrared
spectroscopy (DCE-NIRS) and diffuse correlation spectroscopy (DCS) with semi-infinite head model of photon
propogation. Continuous CBF is obtained via calibration of the DCS blood flow index (BFI) with absolute CBF
obtained by intermittent intravenous injections of the optical contrast agent indocyanine green. A calibration coef-
ficient (γ) for the CBF is thus determined, permitting conversion of DCS BFI to absolute blood flow units at all other
times. A study of patients with acute brain injury (N ¼ 7) is carried out to ascertain the stability of γ. The patient-
averaged DCS calibration coefficient across multiple monitoring days and multiple patients was determined, and
good agreement between the two calibration coefficients measured at different times during single monitoring
days was found. The patient-averaged calibration coefficient of 1.24 × 109 ðmL∕100 g∕minÞ∕ðcm2∕sÞwas applied
to previously measured DCS BFI from similar brain-injured patients; in this case, absolute CBF was underesti-
mated compared with XeCT, an effect we show is primarily due to use of semi-infinite homogeneous models
of the head. © The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of this
work in whole or in part requires full attribution of the original publication, including its DOI. [DOI: 10.1117/1.NPh.5.4.045006]
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1 Introduction
Brain-injured patients are prone to development of secondary
brain injury during the management period, and therapeutic
interventions for secondary brain injury hold potential for mean-
ingful impact on long-term patient outcome.1 More specifically,
clinical studies suggest that brain-injured patients with impaired
cerebral autoregulation are unusually susceptible to secondary
ischemic insult2,3 and that when cerebral blood flow (CBF)
drops below a critical threshold, the development of irreversible
tissue damage can occur;4 whereas if CBF exceeds the brain’s
metabolic requirement, unregulated hyperemia can cause brain
edema.5–7 Thus, CBF monitoring during the management period
can improve acute care via rapid detection and resultant therapy
to attenuate conditions that can lead to secondary brain injury.1
To date, several measurement methods, including PET,8
MRI,9 Xe133,10 Xe-CT,11,12 transcranial Doppler,13,14 thermal
diffusion,15 jugular bulb oximetry,16 and EEG17,18 have been
utilized to infer or to directly evaluate CBF, but none of these
offers truly continuous noninvasive absolute CBF monitoring
capabilities at the bedside. The present study explores the poten-
tial of a combination of near-infrared (NIR) optical methods for
noninvasive continuous bedside monitoring of absolute CBF in
a cohort of adult human patients with brain injury. Thus, patient
treatment needs not be interrupted, and risks of secondary
insults from patient transport (e.g., to MRI, PET instruments)
are reduced. The approach uses time-resolved dynamic
contrast-enhanced near-infrared spectroscopy (DCE-NIRS) to
calibrate the blood flow index (BFI) determined by diffuse cor-
relation spectroscopy (DCS); similar brain volumes are sampled
by the two techniques, and the same light transport model is
used for data analysis and generation of DCS calibration coef-
ficients. The calibrated BFI subsequently permits continuous
bedside monitoring of CBF in physiological units, e.g., mL
of blood∕100 g∕min.19,20 In this contribution, to establish the
repeatability of the calibration coefficients, we cross calibrate
these two quantitatively different and complementary NIR opti-
cal blood flow (BF) measurement techniques at different time
points during the care of a cohort of patients with acute brain
injury. We also determine an average calibration coefficient
based on data across multiple monitoring days and multiple
patients. Finally, we apply this calibration coefficient to assess
flow in critically ill patients with subarachnoid hemorrhage
from a previous study carried out in our groups.21
DCS employs NIR light to directly and noninvasively mea-
sure local microvascular CBF.22–26 This optical technique is*Address all correspondence to: Lian He, E-mail: lianh@sas.upenn.edu
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suitable for continuous bedside monitoring; it has excellent
temporal resolution,27 offers penetration into cerebral tissues
through intact scalp and skull,28 and is compatible for combined
use with traditional NIRS devices.21,25,29–31 To date, DCS-
measured relative BF changes have been extensively validated
in many tissues and against numerous other techniques,21,23 but
the DCS BFI has unusual units (cm2∕s). Absolute calibration of
DCS in traditional units (mL∕100 g∕min) would enable other
useful CBF assessments of the physiological condition of brain-
injured patients, e.g., at baseline and via patient comparison.
Recently, a DCE-NIRS method that employs injection of
a light-absorbing optical contrast agent, indocyanine green
(ICG), was demonstrated to measure absolute CBF.19,32–34
Specifically, the time-dependent absorption signal of an ICG
bolus through cerebral tissue enables measurement of absolute
CBF at a single time point. This approach was applied to mea-
sure CBF in piglets and adult pigs,20,32,35 newborn infants,36,37
and healthy adults.34,38,39 Notably, in a piglet study, comparisons
of DCE-NIRS and CT perfusion measurements showed good
agreement.32 Unfortunately, absolute CBF measurement by
DCE-NIRS requires injection of an ICG bolus and is also lim-
ited by a maximum recommended daily dose; both factors are
barriers to continuous CBF monitoring.
Here, we investigate a scheme for noninvasive continuous
bedside monitoring of absolute CBF in adult human brain-injured
patients based on a combination of time-resolved DCE-NIRS and
DCS. By comparing DCE-NIRS to concurrent DCS measure-
ments, a calibration coefficient for the CBF is determined that
permits conversion of DCS BFI into absolute BF units at
other times during injury management. The concurrent measure-
ments enabled assessment of the stability of ICG calibration
coefficients obtained from each patient across single monitoring
days. We found excellent agreement between the two calibration
coefficients across single monitoring days. Additionally, we
determined a patient-averaged calibration coefficient for DCS
monitoring of absolute CBF. Significant correlation between
CBF obtained with two optical techniques was also observed.
Finally, the population-averaged calibration coefficient was
applied to a group of adult brain-injured patients studied previ-
ously by our group,21 thereby taking first steps toward using DCS
directly as a measure of absolute CBF. In total, the research
suggests that the combined DCS and DCE-NIRS method should
enable improved continuous, noninvasive, and quantitative DCS
monitoring of absolute CBF at the bedside in the clinic.
2 Methods
2.1 Dynamic Contrast-Enhanced Time-Resolved
Near-Infrared Spectroscopy
The DCE-NIRS technique treats the brain vascular bed as a lin-
ear, time-invariant system with single entrance and exit. CBF
can be measured using DCE-NIRS by tracking the concentration
of a NIR tracer in the brain vascular bed.32,40,41 Specifically,
when a bolus of ICG-tracer is injected intravenously in a periph-
eral or central vein, then the rate of delivery of ICG to the brain
vascular bed at time t is CBF · CaðtÞ, where CaðtÞ [μmol · L−1]
is the cerebral arterial ICG concentration (per volume of blood).
If the amount of ICG in brain tissue varies linearly with respect
to the arrival rate, and if CBF is constant in time (i.e., during
the measurement), then the accumulated ICG concentration
(per volume of tissue) in the brain tissue at time t, i.e., QðtÞ
[μmol · L−1] is32,33
EQ-TARGET;temp:intralink-;e001;326;752 ðtÞ ¼ CBF · CaðtÞ  RðtÞ; (1)
where * is the convolution operator, and RðtÞ is the so-called
impulse residue function, which can be viewed as the fraction
of ICG remaining in cerebral vascular bed at time t following an
instantaneous ICG bolus into the arterial input at time zero, i.e.,
Ca;0δðtÞ. Deconvolution with respect to QðtÞ and CaðtÞ permits
CBF · RðtÞ to be extracted.33 The magnitude of CBF · RðtÞ
at the initial time gives absolute CBF ½mL∕100 g∕min as
Rð0Þ ¼ 1. (Note, a cerebral tissue density of 1.05 g∕mL was
used to convert the CBF units of mL∕100 mL∕min obtained
from the deconvolution to mL∕100 g∕min.)
We used time-resolved NIRS (TR-NIRS) to measureQðtÞ on
the forehead superior to the frontal sinuses [Fig. 1(a) and
Sec. 2.1.1]. The width of QðtÞ is a metric of how quickly the
ICG bolus passes through the TR-NIRS sampled tissue volume
[Fig. 1(c)]. Note, a previous study demonstrated high correlation
(slope not significantly different from unity) between CaðtÞ
measured noninvasively with a dye densitometer attached to
the finger and measured invasively through the radial artery.42
Assuming that the ICG concentration in the radial artery and
the cerebral arteries have the same temporal shape CaðtÞ is
approximated by the arterial ICG concentration in the finger,
i.e., CfingerðtÞ measured with a custom dye densitometer
[Fig. 1(c), Sec. 6 Appendix 1]. The injected ICG bolus arrives
at the cerebral arteries earlier than it arrives in the finger arteries.
Therefore, the arterial ICG bolus transit time-delay between the
finger arteries and the cerebral arteries, i.e., ta is a fitting param-
eter in the deconvolution of Eq. (1), and the experimentally
derived deconvolution [e.g., Fig. 1(d)] is CBF · Rðt − taÞ.
The shape of CaðtÞ was assumed to be similar to the shape
of CfingerðtÞ, i.e., CaðtÞ ¼ Cfingerðt − taÞ.
2.1.1 Tissue ICG concentration measurement with
TR-NIRS
TR-NIRS delivers short NIR light pulses (<100 ps) to a source
position on the scalp; the pulse broadens as it propagates
through tissue. At the detector, located a distance r ¼ 3.2 cm
away from the source on the scalp surface, the so-called tempo-
ral point spread function (TPSF) is measured, which is a histo-
gram of the number of photons striking the detector as a function
of the time difference, T̃, between the TR-NIRS source pulse
trigger and the detection of photons [Fig. 1(b), histogram bin
width 1 ps]. To track the kinetics of ICG passage through the
sampled tissue volume following intravenous bolus injection,
TPSFs were continuously acquired at a single wavelength
(808 nm) at a sampling rate of 0.9 Hz (i.e., histogram integration
time of 1.1 s). Note that the time-domain photon diffusion equa-
tion models the distribution of photons as a function of photon
time-of-flight through the tissue, i.e., ϕðTÞ, which is not iden-
tical to the experimentally measured TPSF because of instru-
ment response function (IRF) effects. Using a semi-infinite
homogeneous tissue model, the temporal cerebral tissue absorp-











Here T ≈ T̃ − T̃0, where T̃0 is the maximal photon count bin of
the IRF measurement [Fig. 1(b), Sec. 2.3.2], I0ðTÞ is the mean
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TPSF acquired across the 30-s interval immediately prior to
injection of the ICG bolus [Fig. 1(b)], ItðTÞ is the TPSF mea-
sured at time t following ICG bolus injection, c is the speed of
light in tissue, and the limits T1 and T2 can be chosen to bound
any time interval within the TPSF. In our study, T1 was
chosen to be the time-of-flight with maximal photon count at
baseline, i.e., I0ðT1Þ ¼ maxðI0Þ, and T2 was the time for the
baseline TPSF to fall to half the maximal photon count, i.e.,
I0ðT2Þ∕I0ðT1Þ ¼ 0.5; T2 > T1. T1 and T2 were chosen to
roughly balance between increased brain sensitivity (long time-
of-flights) and adequate signal-to-noise ratio (very long time-of-
flights have poor signal-to-noise ratio). Note, long times-
of-flight are also more susceptible to fluorescence light.44
For T1 < T < T2, Eq. (2) makes the approximation that
ln½ItðTÞ∕I0ðTÞ ≈ ln½ϕtðTÞ∕ϕ0ðTÞ, where ϕtðTÞ and ϕ0ðTÞ
denote the semi-infinite photon diffusion model computations
of the photon distributions given the tissue absorption and scat-
tering optical properties at time t and baseline, respectively.
Note, according to our computer simulations with varied IRF
temporal width, about 10% underestimation in CBF should
be expected when using Eq. (2) to analyze experimentally mea-
sured TPSF, i.e., compared with an ideal TPSF with no broad-
ening of the laser pulse due to electro-optical components.
Moreover, we found that the CBF calculation is not very sensi-
tive to the width of IRF [using Eq. (2)], i.e., <5% difference
between IRF full-width at half-maximum ðFWHMÞ ¼ 180
versus 550 ps.
The ICG concentration in brain tissue is then calculated from
the Beer–Lambert law, i.e.,
EQ-TARGET;temp:intralink-;e003;326;247 ðtÞ ¼ ΔμaðtÞ∕½lnð10Þ × εICG; (3)
where εICG is the spectral extinction coefficient of ICG in
plasma measured at 808 nm and 6.5 μM concentration
(191 OD∕mM∕cm45), and ΔμaðtÞ is obtained via Eq. (2). Note
that Eq. (3) assumes that changes in tissue absorption from
chromophores other than ICG are negligible.
2.2 Diffuse Correlation Spectroscopy
DCS delivers highly coherent NIR light to a source position on
the scalp, which then propagates diffusively inside the tissue.
At a distance r from the source, measured along the tissue
surface, the rapid speckle intensity fluctuations of the multiply
scattered light are measured.22,23,46–52 Specifically, these fluctu-
ations, which are mainly induced by red blood cell motion,
Fig. 1 (a) DCE-NIRS measurement of absolute CBF utilizes TR-NIRS to track the passage of an ICG
bolus [rapidly injected (<2 s) in a peripheral (location A) or central vein (location B)] through the tissue
sampled by the optical probe. The average ICG concentration across the tissue volume, i.e., QðtÞ, is
measured by TR-NIRS (Sec. 2.1.1). The cerebral arterial ICG concentration is approximated using
the arterial ICG concentration in the finger, i.e., C fingerðtÞ, which is measured with a customized dye den-
sitometer (Sec. 6 and Appendix 1). (b) Exemplar effects on the TR-NIRS signals from a 0.2 mg∕kg IV ICG
bolus injection. Note, the TR-NIRS measurement is a histogram of the number of photons striking the
detector as a function of the time difference, T̃ , between the TR-NIRS source pulse trigger and the
detected photons. The TR-NIRS measurement acquired at the time of maximal ICG concentration in
the brain [i.e., I t ;maxðT̃ Þ is attenuated relative to the baseline TR-NIRS measurement acquired prior
to ICG injection [i.e., I0ðT̃ Þ]. Here, T̃ 0 denotes the maximal photon count bin of the IRF, and T̃ 1
and T̃ 2 denote the histogram bins with maximal and half-maximal photon counts in the I0ðT̃ Þ curve.
(c) Temporal measurements of QðtÞ [via Eq. (2)] and C fingerðtÞ in the same exemplar patient. The
peak value of QðtÞ corresponds to an 0.065 cm−1 absorption change due to ICG. (d) The CBF-scaled
impulse residue function, RðtÞ, retrieved from the deconvolution of the curves in (c). The height of the
initial plateau yields CBF (18 mL∕min ∕100 g). Here, t a (2 s) is the arterial ICG bolus transit time delay
between the finger arteries and the cerebral arteries, which is a fit parameter in the deconvolution.
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are quantified by the normalized intensity autocorrelation
function, g2ðr; τÞ ≡ hIðr; tÞIðr; tþ τÞi∕hIðr; tÞi2, where Iðr; tÞ
is the detected light intensity at time t and distance r from
the source, τ is the delay-time, and the angle brackets, h i, re-
present time-averages. The intensity autocorrelation function
is related to the electric field autocorrelation function,G1ðr; τÞ ≡
hEðr; tÞ · Eðr; tÞi, by the Siegert relation, g2ðr; τÞ ¼ 1þ
βjG1ðr; τÞ∕G1ðr; 0Þj2.46,47 G1ðr; τÞ satisfies the correlation dif-
fusion equation in highly scattering media, and β is a constant
that is inversely proportional to the number of speckles detected.
The tissue BFI and the parameter β are extracted from the fit
of the measured g2ðτÞ to the homogeneous continuous-wave sol-
ution of the correlation diffusion equation in the semi-infinite
geometry via the Siegert relation. (Limitations of the semi-infin-
ite model are explored in Sec. 4.) The semi-infinite solution is
















r2 þ ðz0 þ 2zbÞ2
p
, k0 ¼ 2πn∕λ, n is the tissue index of refrac-
tion (i.e., 1.4), λ is the DCS light wavelength (i.e., 785 nm in the
present study), μa is the tissue optical absorption coefficient, μ 0s
is the tissue reduced-scattering coefficient, z0 ≈ 1∕ðμa þ μ 0sÞ is
the effective depth of the source, zb ¼ 2Dð1þ ReffÞ∕ð1 − ReffÞ
is the distance at which the fluence rate extrapolates to zero,
D ¼ 1∕½3ðμa þ μ 0sÞ is the diffusion constant, and Reff is an
effective Fresnel reflection coefficient. For the present study,
the index of refraction of the optical probe was approximately
equivalent to the tissue, i.e., Reff ¼ 0, and we concurrently mea-
sured μa and μ 0s with TR-NIRS (see Sec. 7 and Appendix 2).
Although the DCS BFI has nontraditional units (cm2∕s) for
flow, BFI has been shown to be directly proportional to tissue
BF, i.e., BF ¼ γ · BFI, where γ is a constant; this relationship
has been observed by comparison with numerous independent
methods.23,53 γ depends on the nature (e.g., arterial/capillary/
venule blood volume fractions) and geometry of the microvas-
culature underneath the probe, tissue heterogeneities underneath
the probe, and tissue optical properties. The DCS calibration
coefficient γ for the brain (in our geometry) enables conversion
of BFI to absolute CBF units, i.e.,
EQ-TARGET;temp:intralink-;e005;63;296γ ¼ CBF0∕BFI0; (5)
where CBF0 and BFI0 are the CBF measured by DCE-NIRS and
the BFI measured by DCS at the time of ICG bolus administra-
tion, respectively. The calibration coefficient γ has units of
½ðmL · 100 g−1 · min−1Þ∕ðcm2∕sÞ. In practice, the DCS meas-
urement was not acquired simultaneously with the DCE-NIRS
measurement. Therefore, BFI0 at the time of ICG bolus admin-
istration was estimated from spline interpolation (implemented
in MATLAB R2016a, Mathworks, Natick, Massachusetts) of
the DCS BFI measurements made within the 10-minute interval
encompassing the ICG bolus injection (Fig. 2). Alternatively,
BFI0 can also be interpolated (with similar accuracy) by aver-
aging two BFI measurements taken before and after ICG bolus
injection. Absolute DCS BF is achieved by multiplying the mea-
sured BFIs and γ at all other times during optical monitoring.
The primary goal of this clinical study is to determine and
characterize γ in critically brain-injured adult patients using in-
dependent measurements of CBF with DCE-NIRS at multiple
points in time. A secondary goal is to investigate the accuracy
of direct absolute CBF calibration by applying this γ coefficient
to DCS-measured BFI from another group of brain-injured
patients.
2.3 Instrumentation
Our custom-built instrument consists of a TR-NIRS module for
measurement of tissue optical properties (μa and μ 0s) and ICG
tissue concentration, and a DCS module for measurement of
CBF (i.e., BFI). The TR-NIRS light source is a commercial
supercontinuum fiber laser (SuperK Extreme EXR-20, NKT
Photonics Inc., Morganville, New Jersey) that emits short
white-light pulses (400 to 2400 nm, seed pulse width ∼5 ps)
at a repetition rate of 78 MHz. The fiber laser was connected
to an acousto-optic tunable filter (SuperK Cross, NKT
Photonics Inc.) for programmable selection of specific wave-
lengths. The spectral width for 808 nm is 11 nm, and the switch-
ing time between the wavelengths is 200 ms. This light was
delivered to tissue via a SuperK Connect fiber delivery system
(FD7, NKT Photonics Inc.). Two hybrid single-photon sensitive
photomultiplier tubes (PMA hybrid 50, Picoquant Photonics
Inc., West Springfield, Massachusetts) were connected to
a two-channel time-correlated single-photon counting module
(HydraHarp 400, Picoquant Photonics Inc.) and were used
for TR-NIRS photon time-of-flight measurements (1 ps resolu-
tion). The PMA hybrid detectors were equipped with electrically
controlled shutters that were open only during TR-NIRS acquis-
ition, and 665-nm long-pass colored glass filters (RG-665,
Edmund Optics, Barrington, New Jersey) were installed to
block visible room light. Ideally, a bandpass filter should be
used to filter fluorescence from the excited ICG circulating
in the brain tissue.44,54 However, due to the required switching
between instrument operation modes, the fluorescence filter was
not applied in this study. To ameliorate fluorescence effects,
we calculated absorption changes from the integral of TPSF
in Eq. (2) and we utilized carefully selected time-of-flight
intervals44 wherein fluorescence contributions would be compa-
ratively small.
The DCS light source is a continuous wave, long coherence
length (≥8 m) 785-nm diode laser (IBEAM-SMART-785-S-WS
with Smartdock fiber coupler, Toptica Photonics Inc., Victor,
New York) connected to a fiber-coupled electrically controlled
Fig. 2 An example showing the use of spline interpolation to estimate
BFI0, i.e., the BFI at the time of ICG bolus injection. The red circles are
continuously measured BFIs prior to and after the ICG injection. The
dashed blue line is calculated by spline interpolation of the BFIs mea-
sured with DCS across the 10-min interval starting 5 min before
the injection. The filled green circle is the interpolated BFI at the ICG
bolus injection time.
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shutter (OZ Optics, Ottawa, Ontario, Canada) for gated light
delivery to tissue. DCS measurements of NIR light intensity
correlations (10 Hz sampling rate) were made with four arrays
of four high-sensitivity single-photon counting avalanche
photodiodes (Excelitas SPCM-AQ4C, Pacer LLC, Palm
Beach Gardens, Florida) connected to a multiple-τ 16-channel
hardware correlator (Correlator.com, Bridgewater, New Jersey)
operating in a burst mode.55 For more details about DCS
and TR-NIRS instrumentation, we refer readers to recent
reviews.22,51,56,57
2.3.1 Optical probe
The optical probe used four 4-m long optical fiber bundles
terminated with 3-mm right-angle prisms (MRA03-E03,
Thorlabs, Newton, New Jersey) for tissue measurement
(Fig. 3). The fiberoptic bundles were assembled by Fiberoptic
Systems, Inc. (Simi Valley, California). Light emitted from
the TR-NIRS and DCS lasers was delivered to the same
location on the tissue via the source bundle [labeled a in
Fig. 3(b)], i.e., a bundle of three graded index multimode
fibers (62.5-μm core/0.275 NA; GIF625, Thorlabs); 1 for
TR-NIRS, 1 for DCS, and 1 extra.
For the DCS long source–detector separation (SDS)
measurement, light emerging from the tissue at a distance
r ¼ 2.5 cm from the source was detected with a bundle
of 16 single-mode fibers [5-μm core/0.13 NA, 780 HP,
Thorlabs, labeled c in Fig. 3(b)]; 15 of these fibers were con-
nected to detection channels in the DCS instrument (1 fiber
per channel). The 15 independent intensity autocorrelation
functions acquired in parallel (at the “same” detector position)
were subsequently averaged together to improve signal-to-
noise ratio.
For the TR-NIRS long SDS measurement, light emerging
from the tissue at a distance r ¼ 3.2 cm from the source was
detected with a bundle of 24 multimode fibers [200-μm core/
0.22 NA, Fiberoptic Systems, labeled d in Fig. 3(b)] connected
to a PMA hybrid detector. The optical probe also contained a
hybrid TR-NIRS/DCS detection bundle [labeled b in Fig. 3(b)]
for TR-NIRS and DCS measurement at 0.7-cm SDS. Following
a procedure described elsewhere, the optical fiber bundles
were embedded at precise positions in urethane rubber.28 Note,
a first-generation optical probe (rather than the standard probe)
was employed for some of the measurements in one patient;
in this patient, the source–detector distance may have varied
slightly across monitoring days and would have contributed
to larger-than-normal variations in calibration.
The optical probe was secured to the forehead superior to the
frontal sinuses with sweat-resistant double-sided tape (in contact
with skin: #1522, 3M Health Care, St. Paul, Minnesota; in con-
tact with probe: #9917, 3M) on the bottom of the probe (four
holes were cut in the tape at the four prism locations, such that
the tape did not cover the prisms), and medical tape (Medipore
Dress-It, #2954, 3M) around the edges of the top of the probe.
Further, a black cloth that spanned ∼2 to 3 cm from the edges of
the probe was taped down to block stray light.
In this paper, a semi-infinite tissue model of the head was
utilized for the long TR-NIRS and DCS SDS measurements.
The limitations of the semi-infinite model are explored in Sec. 4.
Fig. 3 Schematic of the optical probe used for TR-NIRS measurement of tissue optical properties and
DCSmeasurement of BFI (see main text for details). (a) The optical probe consists of prism-coupled fiber
bundles embedded in urethane rubber (the prism-fiber connection is protected by an aluminum cap
depicted on the right). It is secured to the forehead superior to the frontal sinuses with double-sided
tape on the bottom and medical tape around the top (see Sec. 2.3.1). (b) The optical probe uses
four fiberoptic bundles (labeled a, b, c, d) for TR-NIRS measurements at 0.7- and 3.2-cm SDS, and
DCS measurements at 0.7- and 2.5-cm SDS. In this paper, a semi-infinite tissue model of the head
was utilized for the long TR-NIRS and DCS SDS measurements (see Secs. 2.1.1, 2.2, and 4).
(c) Schematic of the TR-NIRS IRF measurement (side view; see Sec. 2.3.2). As the urethane rubber
mold could not be bent 90 deg to place the source (position a) and detector (position d) prisms in direct
contact, right-angle prism mirrors were used instead to direct the light from source to detector.
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2.3.2 Instrument response function measurement
The urethane rubber securing the prisms in place could not be
bent to place the source (position a) and detector (position d)
prisms in direct contact (Fig. 3). Therefore, the TR-NIRS
IRF was measured using right-angle prism mirrors to direct
the source light to the detector as shown in Fig. 3(c). To attenu-
ate light properly and provide a wide angular distribution of the
light,58 an 8.0 optical density (OD) neutral density filter (two
sheets, 54-459, Edmund Optics) and one one-ply sheet of kim-
wipe (KW32, Thorlabs), i.e, as a diffuser, were placed in the
middle of the light path. (Note, for fibers with larger NA, it
is recommended that the diffuser be attached close to the tip
of the detection fibers.) The FWHM bandwidth of the IRF
was 190 ps at 14 mW output power emerging from the source
fiber (808-nm wavelength). The FWHM of the IRF is narrow
compared with the typical width of the TPSF from brain tissue
(i.e., FWHM ≈ 830 ps at 3.2-cm SDS). The IRF measurement
was used to define the launch time of the incident source pulse in
the calculation of the absorption change induced by ICG injec-
tion; it was also used to extract optical properties at 786 nm from
the TR-NIRS measurement which, in turn, was used in the DCS
fittings to derive DCS BFI.
2.4 Monitoring Protocol
Optical data acquisition was controlled with a custom-written
software in the Labview environment (National Instruments,
Austin, Texas). The instrument was used in two modes of
operations (Fig. 4): (1) TR-NIRS measurement of absolute
tissue optical absorption (μa) and tissue optical reduced scatter-
ing (μ 0s) coefficients at six wavelengths (730, 750, 786, 810,
830, 850 nm; 800-ms exposure time per wavelength) with
DCS measurement (10 s exposure time) of BFI and (2) ICG
concentration measurement. In the first mode, the instrument
sequentially interleaved TR-NIRS tissue measurements at six
wavelengths with a DCS measurement (10 s exposure). This
enabled us to derive μa and μ 0s, and BFI every 20 s. The multi-
spectral measurements of tissue optical absorption, which were
made for the estimation of total hemoglobin concentration and
tissue oxygen saturation, are not the focus of this paper. Only the
optical properties from the 786-nm wavelength were used in this
study to extract DCS BFI.
In the second mode, cerebral tissue ICG concentration and
arterial ICG concentration were monitored with single-wave-
length TR-NIRS (808 nm, 1 Hz) and customized dye densitom-
etry (see Sec. 6 and Appendix 1), respectively, to track the
kinetics of ICG passage through the brain following intravenous
bolus injection.19,20 A 2-min baseline measurement was made
prior to ICG bolus injection, and 2-min continuous monitoring
was carried out after the injection. After completion of this pro-
cedure, the instrument was switched back to the first operation
mode. Two ICG bolus injections, spaced 4 h apart, were given
per subject monitoring day.
2.5 Patient Population and Study Design
Seven adult patients in the neurointensive care unit were studied
(six males, one female, age 43.9 13.5 years). The enrolled
patients were diagnosed with traumatic brain injury (N ¼ 3),
intracerebral hemorrhage (N ¼ 2), or postischemic encepha-
lopathy (N ¼ 2). Patients were recruited through the
Departments of Neurology and Anesthesiology and Critical
Care with the Neurosurgery Clinical Research Division at the
Hospital of the University of Pennsylvania. Written consent
for all subjects was provided by legally authorized representa-
tives, and all protocols/procedures were approved by the
Institutional Review Board at the University of Pennsylvania,
which adheres to the guidelines of the Common Rule and the
Food and Drug Administration’s Institutional Review Board’s
human subject regulations. Approximately four days of subject
monitoring for eight hours on each day were targeted, though
this goal was not always feasible due to clinical care needs.
On each subject monitoring day, the optical probe was
secured above the fronto-parietal cortex (see Sec. 2.3.1) and
the customized dye densitometer was secured to the subject’s
index finger (see Sec. 6 Appendix 1). Approximately 8 h of con-
tinuous optical measurements were acquired (as described in
Sec. 2.4), and two intravenous ICG bolus injections (0.1 or
0.2 mg∕kg; <2 s per injection) were administered ∼4 h apart
to calibrate the DCS BFI for absolute CBF measurement (see
Fig. 5 for an example).19,20 Note, ICG is cleared from the
body in ∼20 min, and thus the calibration data could in prin-
ciple have been taken more often. The 4-h time window we
chose represents a compromise between the technical challenges
of ICG injection, i.e., patient consent, ICG costs, and clinical
Fig. 4 Schematic of monitoring protocol (Sec. 2.4). During each monitoring day, TR-NIRS and DCS
continuously measured tissue optical properties (μa and μ 0s) and BFI (pink boxes, instrument mode
1). For the absolute CBF measurement via ICG bolus injection, continuous single-wavelength
(808 nm) TR-NIRS measurements were made to track the kinetics of the ICG bolus through the
TR-NIRS sampled cerebral tissue (green boxes, instrument mode 2).
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personnel/workflow, against the need to generate adequate sta-
tistics to ascertain calibration. Thus, two calibration coefficients,
γ1 ¼ CBF0;1∕BFI0;1 and γ2 ¼ CBF0;2∕BFI0;2, were obtained for
a single patient across a single day. Here, the subscripts 1 and 2
denote first and second time points, respectively, of the two
ICG injections. These calibration coefficients were compared to
ascertain the stability of the ICG calibration technique according
to Eq. (5). Note, due to clinical-care needs, for some of the
monitoring days only 1 ICG injection was feasible.
We made 44 ICG injections across 24 monitoring days in the
seven critically brain-injured patients. Of these 44 injections,
absolute CBF could not be measured for eight of them;
seven of these eight were due to the insufficient data quality
in the CaðtÞ measurement, and one of the eight was due to sig-
nificant heart rate increase during ICG injection (i.e., heart rate
increased from 95 to 133 bpm) such that CBF was not constant
during ICG bolus. Of the 24 monitoring days, continuous opti-
cal monitoring with two ICG boluses administered 4 h apart was
feasible in 13 cases. Note, five of these monitoring days were for
the cases wherein absolute CBF for one or two of the injections
could not be assessed, for the reasons described above. For four
of these monitoring days, it was only possible to give patients
one ICG bolus. In the remaining 2 days, the optical probe
needed to be removed for a clinical procedure.
3 Results
3.1 DCS Single-Day Calibrations
We calibrated DCS BF twice a day using the DCE-NIRS tech-
nique during the patient monitoring days wherein continuous
BFI monitoring between doses was feasible (N ¼ 13). Figure 6
shows comparison of two calibration coefficients, γ1 and γ2, for
each patient across a single monitoring day. We observed
a largely linear correlation (R2 ¼ 0.80, N ¼ 23, P < 0.01) and
a slope close to unity (slope ¼ 1.02 0.09, here the error is
the 95% confidence interval [CI]) [Fig. 6(a)]. Additionally,
Bland–Altman analysis of these data [Fig. 6(b)] reveals
a mean difference in the two calibration coefficients of
2.7 × 107 ðmL · 100 g−1 · min−1Þ∕ðcm2∕sÞ, which is not
significantly different from zero (p ¼ 0.67 with Wilcoxon
rank sum test). The limits of agreement between the two
calibration coefficients [dashed lines in Fig. 6(b)], within
which 95% of the differences reside are 4.7 × 108 and
−4.2 × 108 ðmL · 100 g−1 · min−1Þ∕ðcm2∕sÞ. This 95% CI
(4.4 × 108) divided by the mean of the two calibration
coefficients ½1.42 × 109 ðmL · 100 g−1 · min−1Þ∕ðcm2∕sÞ is
31%. Thus, the DCE-NIRS technique for DCS BF calibration
is quite stable across a single monitoring day for a single patient.
We used the coefficient of variation (CV) to evaluate the
stability of same-day calibration within a single subject.
The CV across a single monitoring day was defined as
jγ2 − γ1j∕0.5ðγ2 þ γ1Þ. Across 13 monitoring days, CV was
6.7 4.1% (mean SD). This result indicates that if each
patient receives one-time DCS calibration for absolute CBF,
then absolute CBF is expected to exhibit ∼7% variation
after ∼4 h.
3.2 DCS Calibration across Multiple Days
The absolute CBF measured with DCE-NIRS across all patients
and all monitoring days was significantly correlated with
the absolute BFI measured with DCS [R2 ¼ 0.89, N ¼ 36,
P < 0.01 with F-test, see Fig. 7(a)]. Note, as DCE-NIRS and
DCS sample similar brain volumes, and since both data analyses
employed a semi-infinite head model, we forced the intercept to
be zero in the linear regression analysis. We can derive a “best”
DCS calibration coefficient from the slope (95% CI) of the best-
fit line, i.e., γ¼ð1.240.08Þ×109 ðmL∕100 g∕minÞ∕ðcm2∕sÞ.
We then applied this estimate to all measurements in the same
data to convert the DCS BFI to absolute CBF, i.e., CBFDCS ¼
γ × BFI, and we performed a Bland–Altman analysis to assess
error in CBFDCS. The Bland–Altman analysis reveals that
a mean difference in CBF measured by two techniques, i.e, by
Fig. 5 Continuous calibrated absolute CBF measurements with DCS (red dots) and DCE-NIRS
measurement of absolute CBF via intravenous ICG bolus injection (blue dots) in an exemplar patient
diagnosed with traumatic brain injury. Here, the DCS measurements were calibrated with the first
DCE-NIRS CBF measurement. This patient was continuously monitored for 4 days. For each monitoring
day, two ICG bolus injections were administered 4 h apart.
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DCS and DCE-NIRS, of 0.82 mL∕100 g∕min, is not signifi-
cantly different from zero (p ¼ 0.47 with Wilcoxon rank sum
test) [Fig. 7(b)]. The limits of agreement between the two
CBF measurement techniques [dashed lines in Fig. 7(b)],
within which 95% of the differences resides, are −10.43
and 12.08 ðmL · 100 g−1 · min−1Þ. The 95% CI [i.e.,
11 ðmL · 100 g−1 · min−1Þ] divided by the mean CBFICG [i.e.,
29 ðmL · 100 g−1 · min−1Þ] is 38%. Thus, a single CBFDCS
measurement is expected to be within 38% of the actual CBF.
We used CV to evaluate the stability of calibration across
multiple monitoring days within a single subject. Here, a single
calibration coefficient was obtained for each monitoring day
(i.e., the mean of γ1 and γ2, or just γ1 if only one ICG injection
was made). The CV coefficient for each patient is defined as the
standard deviation of this calibration coefficient for each patient
across multiple monitoring days divided by their mean. Across
seven patients, CV was 21 14% (mean SD). This finding
indicates that if each patient receives a one-time DCS calibration
for absolute CBF monitoring, then absolute CBF is expected to
exhibit ∼20% variation in the following days.
3.3 Testing Calibrated-DCS for CBF of
Brain-Injured Patients in Prior Study
The strong linear relationship between CBF measured with
DCE-NIRS and DCS BFI across multiple monitoring days
Fig. 7 (a) Absolute BF measured by DCE-NIRS technique (vertical axis) compared with the BFI mea-
sured with DCS (horizontal axis) across N ¼ 36measurements. The black line represents the best linear
fit to the data with the intercept forced to be zero (slope ¼ ð1.24 0.08Þ × 109, R2 ¼ 0.89, p < 0.01 with
F-test). (b) Bland–Altman plot of the difference in absolute CBFmeasurements from DCS and DCE-NIRS
techniques. The solid horizontal line indicates the mean difference between the two parameters
computed across the study population, which is not significantly different from zero (p ¼ 0.47 with
Wilcoxon rank sum test). The dotted line indicates 95% CI limits for agreement. Different colors in
(a) and (b) represent different patients.
Fig. 6 (a) DCS calibration coefficients [unit: (mL · 100 g−1 · min−1Þ∕ðcm2∕sÞ]from first ICG bolus injection
(horizontal axis) and second injection (vertical axis) across N ¼ 13 monitoring days in 7 patients. Bolus
injections are 4 h apart. The black line represents the best linear fit to the data with the intercept forced to
be zero (R2 ¼ 0.80, slope 95CI ¼ 1.02 0.09). (b) Bland–Altman plot of the difference in calibration
coefficients from two ICG injections versus the mean of the two coefficients. The solid horizontal line
indicates the mean difference between the two parameters computed across the study population,
which is not significantly different from zero (p ¼ 0.67 with Wilcoxon rank sum test). The dotted line
indicates 95% CI limits for agreement. Different colors in (a) and (b) represent different patients.
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(Fig. 7) suggests the potential for using DCS BFI directly as
a measure of absolute CBF, i.e., CBFDCS ¼ ð1.24 × 109Þ ×
BFI (see Fig. 7). We tested this approach in an independent data-
set. Specifically, we compared CBFDCS obtained from previous
DCS BFI measurements in seven brain-injured patients (i.e., car-
ried out by our groups and published in Ref. 21) to concurrent
measurements of absolute CBF made with the XeCT technique,
i.e., CBFXeCT. The previous study
21 made BFI measurements on
both sides (bilateral) of the forehead using a DCS SDS of 2.5 cm
and employing a semi-infinite homogeneous tissue model for
the head (i.e., the same theoretical model as used in the present
paper). The CBFXeCT was obtained from averaging of the voxels
on the cerebral cortex under the optical probes.21 During this
prior study, pressors were administered to increase blood pres-
sure, and a second concurrent set of bilateral BFI and CBFXeCT
measurements was obtained for each patient. Thus, 24 concur-
rent BFI and CBFXeCT measurements were obtained across
seven patients.
We converted the prior BFI data to CBFDCS. A linear mixed-
effects model was defined wherein CBFXeCT is the response
variable, CBFDCS is the predictor variable, and patient ID
is the grouping variable. The model was analyzed by the
MATLAB® function fitlme, and the results indicate that
CBFXeCT was significantly correlated with the CBFDCS
(R2 ¼ 0.69, N ¼ 24, P < 0.01 with F-test) (Fig. 8). From the
slope (95% CI) of a linear mixed-effect model, we estimate
(8.0 3.2)-fold difference between CBFDCS converted from
DCS BFI and CBFXeCT, i.e., CBFXeCT ¼ ð8.0 3.2Þ ×
CBFDCS. These systematic differences between DCS-calibrated
CBF and CBFXeCT can be understood, in part, to be a conse-
quence of the semi-infinite model for brain (see below).
4 Discussion
To our knowledge, the present study is the first report of the
calibration coefficient for absolute CBF monitoring with DCS
in critically brain-injured adult patients. Several important pre-
vious studies have demonstrated that the same technique can
be used to convert DCS data into absolute CBF on newborn
piglets19 and babies.36 However, none have tested the stability
of the calibration technique across long time periods. In this
paper, we determine the stability of the calibration technique
and investigate the utility of absolute CBF monitoring by direct
DCS measurement throughout the course of treatment. Note,
the instrumentation represents a state-of-the-art TR-NIRS
and DCS system for various reasons, but such a complex
TR-NIRS is not necessary for continuous absolute CBF
monitoring.
In regard to stability, we found that the DCS calibration
coefficient, γ, remains constant over at least 4 h of monitoring;
good agreement was observed between the two daily calibra-
tion coefficients determined from two ICG bolus injections
administered 4 hours apart [Fig. 6(a)]. Although only 4-h inter-
vals were directly tested, γ should remain stable for longer
intervals, provided probe contact is stable. Intrasubject varia-
tion in γ across multiple days, with probe removal and reappli-
cation between daily monitoring sessions, was larger than the
same-day results, with a mean coefficient of variation across
subjects of 21% 14% (Sec. 3.2). Thus, our results indicate
that when removing the probe and reapplying the probe to
roughly the same location the next day, a change in γ of
∼20% can be expected (at least for the present protocols).
Intrapatient variability, however, is sometimes observed to
be larger across monitoring days. One large variation (marked
with blue) was caused by use of first- and second generations
of the probe (which varied slightly), and resultant variations in
source–detector distance across monitoring days can introduce
discrepancies into the calibration coefficients. In addition,
some patients were observed to experience excessive sweating
during the monitoring, requiring extra tape, and wrapping to
secure the probe; this effect, in turn, could increase probe pres-
sure and cause the calibration coefficient to vary. Generally,
factors such as variation in the physiological state of underly-
ing brain tissue, probe location, and probe pressure against
the head can induce variation in the calibration coefficient.
For this reason, our study utilized daily calibration, and the
study suggests that daily calibration of DCS is optimal.
4.1 Estimation of Absolute CBF from DCS BFI
Measurements
In regard to using the DCS BFI as a direct measure of absolute
CBF, we observed a strong linear correlation (R2 ¼ 0.89)
between absolute CBF measured with DCE-NIRS and DCS
BFI [Fig. 7(a)]. Using the slope of the best fit line as the γ coef-
ficient, estimation of absolute CBF from the DCS BFI is
CBFDCS ¼ ð1.24 × 109ÞBFI. Via Bland–Altman analysis, the
mean difference between CBFDCS and CBF measured with
DCE-NIRS, i.e., CBFICG, was not significantly different from
zero [p ¼ 0.47 with Wilcoxon rank sum test, Fig. 7(b)]. The
variability between CBFDCS and CBFICG, i.e., defined as the
95% CI of their difference divided by the mean CBFICG across
measurements, was 38%. Thus, conservatively, our results sug-
gest that CBFDCS should be within 40% of the CBF, as measured
by DCE-NIRS. Note that the DCS calibration coefficient of
γ ¼ 1.24 × 109 ½ðmL · 100 g−1 · min−1Þ∕ðcm2 · s−1Þ] obtained
for this cohort is comparable with the DCS calibration coeffi-
cient previously obtained in piglets with the same DCE-
NIRS technique, i.e., 1.14 × 109 ½ðmL · 100 g−1 · min−1Þ∕
ðcm2 · s−1Þ, R2 ¼ 0.89.19
Fig. 8 Absolute CBF measured by XeCT technique (vertical axis)
compared with the CBF measured with DCS (horizontal axis) across
N ¼ 24 measurements. The black line represents the best linear fit
to the data with the intercept forced to be zero (slope ¼ 8.0 3.2,
R2 ¼ 0.69, p < 0.01 with F-test). Different colors represent different
patients.
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4.2 CBF Estimates Obtained with Semi-Infinite
Head Model Underestimates True CBF
We used the DCS calibration coefficient, γ ¼ 1.24 ×
109 ½mL · 100 g−1 · min−1Þ∕ðcm2∕sÞÞ, extracted from this
cohort to convert prior BFI data in brain injured patients
(N ¼ 7) to absolute CBF (Sec. 3.3), which again, is denoted
as CBFDCS. In comparison with concurrent CBF measurements
obtained with XeCT, i.e., CBFXeCT, linear regression analysis
showed that although CBFDCS and CBFXeCT were correlated
(R2 ¼ 0.69), CBFDCS underestimated CBFXeCT by roughly a
factor of 8 (i.e., slope 95%CI ¼ 8.0 3.2). We can under-
stand this systematic deviation (see below), but we also note
that the early work had many limitations that could have weak-
ened correlations. For example, the earlier paper assumed rather
than measured tissue optical properties (i.e., μa ¼ 0.11 cm−1
and μ 0s ¼ 12 cm−1) to compute BFI; this approach translates
to errors in BFI.19,59,60 The overall underestimation, however,
largely arises from using the semi-infinite homogeneous head
model for determining γ and BFI (Secs. 2.1 and 2.2).
It is known that the semi-infinite model underestimates
localized CBF changes. In previous measurements of humans
performing a finger tapping task, CBF relative changes com-
puted with the semi-infinite model underestimated the true
changes by a factor of 5.61 This result was subsequently
confirmed in realistic simulations of the head.62 For absolute
CBF estimates on healthy adult subjects with DCE-NIRS,
mean CBF with the semi-infinite model was 8.3 mL∕
100 g∕min, which was believed to have large underestimation
compared with values obtained by PET, i.e., a factor of 6.38,63,64
In two-layer simulations of the head, DCE-NIRS CBF measure-
ments obtained from application of the semi-infinite model to
continuous-wave NIRS data also underestimated the true CBF
by around eightfold.63
To further elucidate this issue, we performed two-layer sim-
ulations of the head to assess underestimation of DCE-NIRS
CBF measurements obtained from application of the semi-
infinite model to simulated two-layer time-resolved NIRS data
(details in Sec. 8 and Appendix 3). Overall, we found that the
underestimation of CBF with the semi-infinite model ranged
from 3.5 to 6.5, with top layer thickness being the most sensitive
parameter for different levels of underestimation (Sec. 8 and
Appendix 3). Thus, the underestimation of CBFDCS compared
with CBF measured from XeCT (slope ¼ 8.0 3.2, N ¼ 24,
R2 ¼ 0.69, Sec. 3.3) partially overlapped with the range of
underestimation found from this computer simulation.
4.3 Limitations
The use of the semi-infinite model for estimation of absolute
CBF with DCE-NIRS is the most significant limitation for
obtaining calibration coefficients in the present paper. Note,
this limitation does not alter the paper’s findings and conclu-
sions about measurement stability. Different algorithms beyond
the semi-infinite model have been proposed to improve the
depth sensitivity of TR-NIRS measurements.20,65–69 One prom-
ising approach is the use of changes in the variance moment
of the TPSF TR-NIRS measurement for retrieval of ICG
concentration.68,70,71 The linearity between changes in the
variance moment of TPSF and changes in absorption holds,
however, only when the changes in absorption are sufficiently
small.70,72 In simulations (see Sec. 4.2), we find that when
the absorption changes are very large due to ICG, then
a substantial underestimation of the cerebral absorption change
is introduced when extracted by the variance moment analysis
(e.g., by ∼72%). To ameliorate this situation in the future, we
will include higher order terms related to the absorption change;
this method permits retrieval of more accurate absolute CBF
and can be applied for bolus injection of ICG at high
concentration.34 In a different vein, the short source–detector
separation data were not used for several reasons. First, the
TR-NIR measurement was not able to generate accurate optical
properties, because the temporal width of IRF and tissue TPSF
curves were too similar (FWHMs are 190 versus 300 ps). Also,
we did not consistently obtain information about scalp and skull
thickness (under the probe), because the necessary CT scans
were not always taken during our optical monitoring session.
Given these sources of error, we felt that only the large
source–detector separations and semi-infinite head models were
justified. In the future, we anticipate that short SDSs for both
TR-NIRS and DCS measurement will be used along with a
layered DCS model for better computation of cerebral BFI,28,73
and absolute DCS CBF calibration coefficient.
5 Conclusion
In this study, we demonstrated the long-term stability of non-
invasive absolute CBF monitoring with DCE-NIRS calibrated
DCS. The calibration was stable across a single monitoring
day, and the variability for each patient across multiple monitor-
ing days was moderate (20% varying between 3% and 40%).
The variability in calibration coefficient across multiple moni-
toring days and multiple subjects was small enough that a strong
correlation between CBF measured with DCE-NIRS and DCS
BFI was observed. However, for single measurements, devia-
tions of up to 40% from the best fit line of DCE-NIRS CBF
to DCS BFI can be an issue for some applications. If feasible,
it is best to calibrate DCS with DCE-NIRS prior to every patient
monitoring session. Finally, the semi-infinite model estimate of
absolute CBF substantially underestimates the true CBF.
6 Appendix 1: Principle of Customized ICG
Dye Densitometer
For measurement of arterial ICG concentration per volume of
blood in the finger, i.e., Cfinger (Sec. 2.1), we used a customized
dye densitometer that consisted of a two-wavelength (804 and
938 nm) finger sensor (TL-301P, Nihon Kohden, Cambridge,
Massachusetts) connected to an integrated analog front-end
commercial pulse oximeter circuit board (AFE4400, Texas
Instruments, Dallas, Texas), which was in turn connected to a
laptop computer. The circuit board cyclically altered illumina-
tion of the finger between wavelengths λ1 ¼ 804 nm and λ2 ¼
938 nm (5-ms exposure per wavelength), and also recorded their
temporal intensities transmitted through the finger, i.e., Ĩ½λ1ðtÞ
and Ĩ½λ2ðtÞ, at 100-Hz sampling rate. Here, we introduce the
principle of extracting CfingerðtÞ from these measurements.
First, a finite impulse response digital bandpass filter with a
passband frequency from 0.95fhr to 1.05fhr, wherein fhr is the
average heart rate across the four-minute interval encompassing
the ICG injection (see Fig. 4, mode 2), was constructed
in the MATLAB R2016a software environment (designfilt,
Mathworks), and applied to Ĩ½λ1ðtÞ and Ĩ½λ2ðtÞ. Hereafter, we
will denote the bandpass filtered data as I½λ1ðtÞ and I½λ2ðtÞ.
The modified Beer–Lambert law74,75 was next employed to
relate the measured peak-to-peak amplitude of the pulsatile
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oscillation during the cardiac cycle in the bandpass filtered
optical density to the peak-to-peak amplitudes of the pulsatile
oscillations in light chromophore concentrations, i.e.,
EQ-TARGET;temp:intralink-;e006;63;719






þ εHb½λΔ½HbRðtÞ þ εICG½λΔ½ICGðtÞd½λ; (6)
where t refers to averaged times across single heart beats (e.g.,
for fhr ¼ 60 bpm, t ¼ 0.5 s, 1.5 s, 2.5 s,. . . ); I1½λðtÞ and I2½λðtÞ
are the peak and minimum bandpass filtered intensities at wave-
length λ, respectively, during the cardiac cycle associated with
the heart beat at time t; Δ½HbOðtÞ, Δ½HbRðtÞ, and Δ½ICGðtÞ
are the differences between the peak and minimum bandpass
filtered oxyhemoglobin, deoxyhemoglobin, and ICG tissue con-
centrations (per volume of tissue), respectively, during the car-
diac cycle at time t; εHbO½λ, εHb½λ , and εICG½λ are the extinction
coefficients of oxyhemoglobin, deoxyhemoglobin, and ICG
(measured at 6.5 μM concentration in plasma), respectively,
at wavelength λ;45 and d½λ is the differential path length at
wavelength λ. Assuming that heart rate induced blood volume
oscillations are (1) faster than changes in chromophore concen-




Δ½HbR ¼ ð1 − SaÞΔ½HbT;
Δ½ICG ¼ CfingerΔ½HbT∕½Hgb; (7)
where Sa is the arterial oxygen saturation, Δ½HbT is the differ-
ence between the peak and minimum bandpass filtered total
hemoglobin concentration (per volume tissue), and ½Hgb is
the total hemoglobin concentration per volume blood. Note,
the time-dependence t is implicit for all parameters in






















Equation (8) is then used to generate a system of two equa-
tions that correspond to the two light wavelengths in the sensor










EQ-TARGET;temp:intralink-;e010;63;112ΔOD½λ2 ¼ d½λ2½εHbO½λ2 · Sa þ εHbR½λ2 · ð1 − SaÞ · Δ½HbT:
(10)




¼D · εHbO½λ1 ·SaþεHbR½λ1 · ð1−SaÞþεICG½λ1 ·Cfinger∕½Hgb
εHbO½λ2 ·SaþεHbR½λ2 · ð1−SaÞ
;
(11)
where D ≡ d½λ1∕d½λ2. D is given by the rearrangement of
Eq. (11) for the baseline time interval that spans the last 30 s
prior to ICG injection (Cfinger;0 ¼ 0 at baseline):
EQ-TARGET;temp:intralink-;e012;326;618
D ¼ φ0½εHbO½λ2 · Sa;0 þ εHbR½λ2 · ð1 − Sa;0Þ∕½εHbO½λ1
· Sa;0 þ εHbR½λ1 · ð1 − Sa;0Þ; (12)
where φ0 and Sa;0 denote the averages of φ and Sa across the
baseline interval. Note, Sa;0 is measured with a clinical pulse
oximeter on the patient. Finally, with D given by Eq. (12),






· ½εHbO½λ2 · Sa;0 þ εHbR½λ2 · ð1 − Sa;0Þ







where the time-dependence t is implicit for Cfinger and φ, and Sa
is approximated as a constant, i.e., Sa;0, for the 4-min interval
encompassing the ICG injection (see Fig. 4, mode 2) because
the acute clinical pulse oximeter measurements following the
ICG bolus injection are not reliable (the presence of ICG indu-
ces an artifactual drop in the clinical pulse oximeter measure-
ment of Sa). ½Hgb is also assumed to be constant, and its
value is obtained from the closest clinical blood gas measure-
ment to the ICG bolus injection. The ½Hgb measurements
were acquired within 12 h of the ICG bolus injections. Note,
differences in ½Hgb between the clinical blood gas measurement
and ICG bolus injection timepoints are sources of errors in
the calculation of Cfinger.
7 Appendix 2: Optical Properties Measured
with TR-NIRS Based on Semi-infinite
Medium
In vivo cerebral tissue optical properties measurements at
λ ¼ 785 nm (μa and μ 0s) were obtained with TR-NIRS.
Specifically, optical properties were extracted from the fits of
TR-NIRS TPSF measurements to the time-domain analytical
solution of the photon diffusion equation for the semi-infinite
homogeneous medium and extrapolated zero boundary condi-
tion,76 i.e.,
EQ-TARGET;temp:intralink-;e014;326;163ϕðr; TÞ ¼ 0.118ϕ1ðr; TÞ þ 0.306ϕ2ðr; TÞ; (14)
where the solution, ϕðr; TÞ, is the sum of two terms that are
proportional to the fluence rate, i.e., ϕ1ðr; TÞ, and to the current
or flux, i.e., ϕ2ðr; tÞ, respectively. The proportionality coeffi-
cients, i.e., 0.118 and 0.306, are based on a refractive index
n ¼ 1.4; T is the time-of-flight along the TPSF curve, and
r is the SDS. For semi-infinite media
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where D, c, z0, zb, r1, and r2 are defined below Eq. (4).
Due to the finite width of the laser pulse and its broadening
by the instrumental response of the measuring system, the mea-
sured TPSF does not represent the true impulse of the tissue. To
account for this, the theoretical curve generated by Eq. (14) is
convolved with the IRF (Sec. 2.3) measured with the same fiber
optics.58 Note that T ¼ T̃ − t0, where T̃ is the time between the
source trigger and photon detection, and t0 is the launch time of
the incident source pulse on the tissue (Sec. 2.1.1). A nonlinear
optimization routine (MATLAB® function fminsearchbnd) was
used to obtain μa, μ 0s, and t0 from the fit of the measured TPSF to
the convolution of the IRF and theoretical TPSF (ϕ), i.e.,
TPSFfit ¼ IRF  ϕ (μa and μ 0s constrained to be between
0.001 and 1 cm−1, and 0.1 and 50 cm−1, respectively; t0 was
constrained to be within 50 ps of the time point when the
IRF maximum occurs). Fitting is the process of minimizing a
cost function between measured TPSF and the TPSFfit, where
the measured TPSF and TPSFfit were normalized to the area
under the curve. The cost function was defined as the sum of
the squared difference between measured TPSF and the
TPSFfit scaled by squared root of measured TPSF at each
time-of-flight. The fitting range was set to time of flights
between the TPSF rising to 20% and falling to 10% of the maxi-
mal photon count.
8 Appendix 3: Computer Simulation
to Evaluate CBF Underestimation
Using Semi-Infinite Model
Computer simulation based on a two-layer model which mimics
the extracerebral, i.e., scalp and skull, and cerebral tissues was




½HbT (μM) SO2 (%) ½Hgb (g/dL) BF (mL∕100 g∕min) Water Content (%) μ 0s (cm−1) μa (cm−1) Layer Thickness (cm)
Extracerebral 42 65 10 10 75 12 0.09 1.2
Cerebral 75 65 10 60 75 12 0.16 Infinite
Fig. 9 Dependence of absolute CBF underestimation with semi-infinite model (i.e., actual CBF divided by
the computed CBF with the semi-infinite model) on (a) extracerebral layer thickness, (b) source–detector
separation for TR-NIRS measurement, (c) CBF, (d) cerebral to extra-CBF, (e) and (f) extracerebral
and cerebral total hemoglobin concentration, and (g) and (h) extracerebral and cerebral tissue reduced
scattering coefficients.
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performed to evaluate the underestimation in DCE-NIRS CBF
measurements with the semi-infinite model. The passage of ICG
bolus was simulated according to Eq. (1), where the arterial
input function, CaðtÞ, was obtained from a patient measurement
with the ICG dose concentration at 0.2 mg∕kg. Note, Eq. (1)
was used twice to compute QðtÞ for the extra-cerebral tissue
[i.e., QecðtÞ] and the cerebral tissue [i.e., QcðtÞ]. The impulse
residue function, RðtÞ, was modeled as an exponential,
i.e., RcðtÞ ¼ expð−t∕mttcÞ and RecðtÞ ¼ expð−t∕mttecÞ for
the cerebral and extra-cerebral tissues, respectively.63 Here,
mttc and mttec are the mean transit times of blood through
the DCE-NIRS sampled cerebral tissue volume and extra-
cerebral tissue volume, respectively. These are estimated
by mttc ¼ ½HbTc∕½Hgb and mttec ¼ ½HbTec∕½Hgb, where
½HbTc and ½HbTec are the total hemoglobin concentrations
(per volume tissue) in cerebral and extra-cerebral tissues
(e.g., measured with NIRS) and ½Hgb is the total hemoglobin
concentration (per volume blood) measured from blood gas, i.e.,
a blood sample is drawn by the clinician in the NICU and is
analyzed by a spectrophotometric measurement in the clinic
labs. The ICG concentration changes in the two layers were fur-
ther converted to temporal absorption changes in the two layers
by multiplying the extinction coefficient, εICG, at wavelength
808 nm according to Eq. (3). Temporal TPSF curves at certain
SDS were generated with a two-layer forward solver (provided
by Liemert and Kienle77) based on these temporal absorption
changes at different layers and on constant cerebral and
extra-cerebral tissue reduced scattering coefficients, tissue
water content, and extra-cerebral layer thickness. Following
the same method used to analyze the experiment data, the
semi-infinite model was used to extract the absorption change
based on the simulated TPSF curves according to Eq. (2), which
was further converted to ICG concentrations. Deconvolution
algorithm was then applied to the extract the absolute CBF
values. The ratio between the simulated and extracted CBF
values was taken to evaluate the underestimation induced by
semi-infinite homogeneous model for a wide range of input
parameters used to generate the simulated TPSF curves.
Specifically, the input parameters for a “baseline
model”62,63,78 for computer simulation are set as shown in
Table 1 with SDS at 3.2 cm. Then, the input parameters
were varied separately from the baseline model while all
other input parameters were held constant (note, the baseline
cerebral to extra-cerebral flow ratio of 6 was held constant
instead of the absolute baseline extra-CBF). Variations in
extra-cerebral layer thickness (from 1 to 1.6 cm), SDS (from
1.2 to 4.2 cm), CBF value (from 40 to 80 mL∕100 g∕min), cer-
ebral to extra-CBF ratio (from 4 to 9 via changing extra CBF),
total hemoglobin concentration in brain tissue (from 40 to
120 μM), total hemoglobin concentration in extra-cerebral
tissues (from 10 to 60 μM), μ 0s in extra-cerebral tissue (from
10 to 16 cm−1),78 and μ 0s in cerebral tissue (from 4 to 12 cm−1)
were tested. Figure 9 shows the dependence of the underestima-
tion on different physiological, anatomical, and optical param-
eters as well as SDS. The range of underestimation varies from
3.5- to 6.0-fold, with extracerebral layer thickness being the
most sensitive parameter.
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